🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal Tumors

RecruitingNAAges 18 Years - anyAllPeking University First Hospital
NCT07875959 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Renal cell carcinoma and renal pelvic urothelial carcinoma are common malignant tumors of the urinary system. Accurate preoperative differentiation between these tumor types is important for treatment planning, while conventional imaging methods may have limitations in characterizing tumor biology. Nectin-4 is a tumor-associated molecular target that is highly expressed in several epithelial malignancies, particularly urothelial carcinoma. 18F-N230A is a novel PET imaging probe targeting Nectin-4. This study aims to evaluate the safety, biodistribution, and imaging characteristics of 18F-N230A PET/CT in patients with suspected or confirmed renal tumors. Participants enrolled in this study will undergo 18F-N230A PET/CT imaging and 18F-FDG PET/CT imaging. The imaging findings and quantitative parameters will be analyzed and compared. Pathological results obtained from surgery or biopsy w

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participants aged ≥18 years. * Patients with suspected or confirmed renal tumors who are scheduled for pathological examination by biopsy or surgical resection within 2 months. * Patients who can understand the study procedures and voluntarily provide written informed consent. * Patients who can cooperate with PET/CT imaging procedures. Exclusion Criteria: * Patients with severe abnormalities in liver function, renal function, or blood cell counts. * Patients unable to understand the study procedures or unable to cooperate with imaging examinations. * Patients with a history of other malignant tumors. * Patients considered unsuitable for participation by the investigator.
💊

What it tests

  • 18F-N230A
📍

Where

1 site
Peking University First Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy